Skip to main content


Fig. 6 | Respiratory Research

Fig. 6

From: The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Fig. 6

Overall survival of IPF patients upon first diagnosis depending on treatment. Given are Kaplan-Meier curves for cumulative survival, based on definite outcome data (survival status definitely known as per end of 2016) and on last visit data. A statistically significant difference in survival was encountered between patients receiving anti-fibrotic treatment and those not receiving antifibrotics, significance level p was 0.001. Within the group of patients receiving antifibrotic treatment, 83% of patients received pirfenidone and 17% received nintedanib

Back to article page